Newswise — PHILADELPHIA — Stand Up To Cancer (SU2C) and the Prostate Cancer Foundation (PCF), along with the American Association for Cancer Research, call upon the cancer research community to submit Letters of Intent for a new Dream Team dedicated to prostate cancer research.
The SU2C-PCF Prostate Dream Team Translational Cancer Research Grant will provide funding of up to $10 million over a three-year period for a cancer research project that will address therapeutic interventions for advanced prostate cancer with special emphasis on metastatic disease, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators. Proposals for the SU2C-PCF Prostate Dream Team Translational Cancer Research Grant must include plans indicating how the work will be translated into the clinic.
To maximize creativity, innovation and collaboration, the Dream Team must include laboratory and clinical researchers, senior and/or young investigators and senior scientists who have not worked together in the past, as well as patient advocates. This Dream Team will span multiple disciplines and utilize the new tools of modern biology to attack research questions in a coordinated way. Mechanisms to foster collaboration within and among the Dream Teams should be employed — an approach that promotes the sharing of information and a goal-oriented focus on measurable milestones of progress.
SU2C and PCF believe that this unique Dream Team model will advance scientific research in the interests of both today’s cancer patients and those who may develop cancer in the future. A SU2C-PCF Joint Scientific Advisory Committee (JSAC) will conduct a unique, rapid and rigorous evaluation of the applications via a multi-step scientific review process. The committee is chaired by Nobel Laureate Phillip A. Sharp, Ph.D., institute professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. It is co-chaired by SU2C representative William G. Nelson, M.D., Ph.D., the Marion I. Knott director and professor of oncology, and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and PCF representative Howard R. Soule, Ph.D., executive vice president and chief science officer of the Prostate Cancer Foundation. The JSAC is comprised of highly accomplished senior laboratory researchers and physician-scientists as well as advocates.
Since the launch of Stand Up To Cancer in 2008, the AACR has played an integral role as SU2C’s scientific partner by providing scientific leadership, expert peer review and grants administration. The AACR is responsible for administering these grants and provides ongoing scientific oversight to ensure that progress is being made. The AACR will work closely with PCF, the world’s leading philanthropic organization funding and accelerating prostate cancer research.
For general information on eligibility criteria, the application process and other details about this Dream Team grant, please visit: www.aacr.org/SU2CPCF. Inquiries may be directed to the SU2C Grants Office at: (267) 765-1049 or [email protected]. Those interested should submit Letters of Intent detailing their best ideas for cutting-edge prostate research projects using the proposalCENTRAL website at https://proposalcentral.altum.com. ProposalCENTRAL will be available by Nov. 15. Letters of Intent must be submitted by 12:00 p.m. (noon) ET on November 28, 2011.
Plans are for the new Dream Team to be announced at the AACR Annual Meeting 2012, held March 31 through April 4 at McCormick Place in Chicago, Ill.
# # #
About Stand Up To CancerStand Up To Cancer (SU2C) — a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization — raises funds to accelerate the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives. SU2C facilitates collaboration among the best and the brightest in the cancer research community. By galvanizing the entertainment industry, SU2C generates awareness and builds grassroots support for this effort.
To view the recently televised Stand Up To Cancer fundraising special, please visit: www.su2c.org/2010show. For general information, please visit www.su2c.org.
About the Entertainment Industry FoundationStand Up To Cancer is a program of the Entertainment Industry Foundation (EIF), the 501(c)(3) not-for-profit organization that serves as the collective philanthropy for the television and film businesses. EIF has distributed hundreds of millions of dollars to support programs addressing critical health, education and social issues.
About the Prostate Cancer Foundation The Prostate Cancer Foundation (PCF) is the world’s leading philanthropic organization funding and accelerating prostate cancer research. Founded in 1993, PCF has raised nearly $475 million and provided funding to more than 1,500 researchers at nearly 200 institutions in 12 countries. PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds supporting transformational cancer research. More information about PCF can be found at pcf.org.
About the American Association for Cancer ResearchThe mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 laboratory, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards to young investigators, and it also funds cutting-edge research projects conducted by senior researchers. The AACR has numerous fruitful collaborations with organizations and foundations in the U.S. and abroad, and functions as the Scientific Partner of Stand Up To Cancer, a charitable initiative that supports groundbreaking research aimed at getting new cancer treatments to patients in an accelerated time frame. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care, and Educational Workshops are held for the training of young cancer investigators. The AACR publishes seven major peer-reviewed journals: Cancer Discovery; Cancer Research; Clinical Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Prevention Research. In 2010, AACR journals received 20 percent of the total number of citations given to oncology journals. The AACR also publishes Cancer Today, a magazine for cancer patients, survivors and their caregivers, which provides practical knowledge and new hope for cancer survivors. A major goal of the AACR is to educate the general public and policymakers about the value of cancer research in improving public health, the vital importance of increases in sustained funding for cancer research and biomedical science, and the need for national policies that foster innovation and the acceleration of progress against the 200 diseases we call cancer.
Visit the AACR: www.aacr.orgFollow the AACR on Twitter: @aacr #aacr Follow the AACR on Facebook: http://www.facebook.com/aacr.org
RSS